Enanta Pharmaceuticals Stock Performance
| ENTA Stock | USD 6.20 0.11 1.74% |
Enanta Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.19, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enanta Pharmaceuticals will likely underperform. Enanta Pharmaceuticals right now shows a risk of 5.48%. Please confirm Enanta Pharmaceuticals sortino ratio, semi variance, and the relationship between the information ratio and value at risk , to decide if Enanta Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Enanta Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Enanta Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Actual Historical Performance (%)
One Day Return (1.74) | Five Day Return (3.12) | Year To Date Return 10.91 | Ten Year Return (80.20) | All Time Return (63.91) |
1 | Enanta Pharmaceuticals Anticipated to Release Quarterly Earnings on Wednesday | 01/29/2025 |
2 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 | 02/10/2025 |
3 | Enanta Pharmaceuticals Reports Q1 EPS Loss of 1.05, Beating Estimates Revenue at 17. ... | 02/12/2025 |
4 | Enanta Pharmaceuticals Moves to Buy Rationale Behind the Upgrade | 02/14/2025 |
5 | StockNews.com Upgrades Enanta Pharmaceuticals to Hold | 02/21/2025 |
6 | Acquisition by Carter Bruce L A of 15700 shares of Enanta Pharmaceuticals at 6.83 subject to Rule 16b-3 | 03/13/2025 |
7 | Acquisition by Foletta Mark G of 15700 shares of Enanta Pharmaceuticals at 6.83 subject to Rule 16b-3 | 03/14/2025 |
8 | Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune Inflammatory Disease Virtual Conference | 03/17/2025 |
| Begin Period Cash Flow | 89.4 M |
Enanta |
Enanta Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 600.00 in Enanta Pharmaceuticals on December 25, 2024 and sell it today you would earn a total of 20.00 from holding Enanta Pharmaceuticals or generate 3.33% return on investment over 90 days. Enanta Pharmaceuticals is currently generating 0.1911% in daily expected returns and assumes 5.4756% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Enanta, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enanta Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enanta Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enanta Pharmaceuticals, and traders can use it to determine the average amount a Enanta Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0349
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ENTA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.48 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Enanta Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enanta Pharmaceuticals by adding it to a well-diversified portfolio.
Enanta Pharmaceuticals Fundamentals Growth
Enanta Stock prices reflect investors' perceptions of the future prospects and financial health of Enanta Pharmaceuticals, and Enanta Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enanta Stock performance.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.58) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | (26.97 M) | ||||
| Shares Outstanding | 21.33 M | ||||
| Price To Earning | 366.13 X | ||||
| Price To Book | 1.18 X | ||||
| Price To Sales | 1.99 X | ||||
| Revenue | 67.64 M | ||||
| Gross Profit | 66.59 M | ||||
| EBITDA | (104.51 M) | ||||
| Net Income | (116.05 M) | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 55.47 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 5.24 X | ||||
| Cash Flow From Operations | (78.76 M) | ||||
| Earnings Per Share | (4.95) X | ||||
| Market Capitalization | 132.26 M | ||||
| Total Asset | 376.65 M | ||||
| Retained Earnings | (323.04 M) | ||||
| Working Capital | 242.32 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
About Enanta Pharmaceuticals Performance
By analyzing Enanta Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Enanta Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enanta Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enanta Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.34) | |
| Return On Capital Employed | (0.44) | (0.42) | |
| Return On Assets | (0.35) | (0.34) | |
| Return On Equity | (1.04) | (0.98) |
Things to note about Enanta Pharmaceuticals performance evaluation
Checking the ongoing alerts about Enanta Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enanta Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enanta Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 67.64 M. Net Loss for the year was (116.05 M) with profit before overhead, payroll, taxes, and interest of 66.59 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (78.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enanta Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune Inflammatory Disease Virtual Conference |
- Analyzing Enanta Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enanta Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Enanta Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enanta Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enanta Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enanta Pharmaceuticals' stock. These opinions can provide insight into Enanta Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |